Upfront Briefing
Third time’s the charm: Replimune got Tudriqev past the FDA in advanced melanoma, two rejections and one 10-3 adcomm later, with a $450,000 list price to show for the wait. Latigo picked the same evening to price an upsized $345.6M IPO at the top of its range, which is a fairly loud way of saying the pain window is open. Tarsus, meanwhile, put $450M into Alkeus for a Stargardt drug whose pivotal data lands in 2029 — patience, or a very long-dated call option, depending on your seat. Elsewhere: earnings, guidance raises and a couple of programs quietly taken out back.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,710.0 |
(0.2%) |
12.4% |
| Nasdaq 100 |
29,373.3 |
(0.4%) |
16.5% |
| Russell 2000 |
3,001.6 |
(0.6%) |
19.7% |
| Healthcare (XLV) |
164.5 |
0.2% |
5.7% |
| Biotech (XBI) |
154.5 |
1.0% |
27.1% |
| Nasdaq Biotech (NBI) |
6,659.1 |
0.4% |
16.7% |
| Clinical Trials (BBC) |
52.0 |
1.7% |
38.3% |
|
- Biotech outran a soft tape — XBI up 1.0%, BBC up 1.7% against a 0.2% S&P decline — as money rotated out of memory and software (Sandisk off 6%, Western Digital 13%, AppLovin nearly 20%) and into defensives, with Moderna’s mFlusiva clearance the prior evening giving the sector a live catalyst.
- The Dow snapped a five-session record run, down 464 points (0.85%), as Brent pushed toward $83 on Iran–Oman talks over reopening the Strait of Hormuz; gold added 1.8% and VIX firmed to 15.27 while the 10-year sat at 4.66%, leaving Friday’s July payrolls as the swing factor after Challenger put July layoffs at a two-year low and claims printed 199,000.
- Market data: U.S. cash close Thursday, 6 August 2026.
The Big 3
|
1
|
FDA approves Replimune's Tudriqev in advanced melanoma
|
- Tudriqev won FDA accelerated approval in advanced melanoma after two earlier rejections and a 10-3 advisory committee vote in favor.
- Why it matters: Accelerated approval rests on a 24.2% ORR and 14.1-month median duration of response among 91 efficacy-evaluable patients — the same single-arm IGNYTE dataset the FDA rejected in July 2025 and again in April 2026. What changed was the 10-3 adcomm, not the data. The $450,000 list price gives Replimune its first product revenue against a going-concern flag, under a year of cash and a proposal to double authorized shares to 300 million; approval also pushes the term-loan maturity from October 2027 to October 2029. IGNYTE-3, roughly 400 patients with OS as primary, reads out in 2027 and can take it all back.
- Source: BioPharma Dive
- More: STAT; Fierce Pharma
|
|
2
|
Latigo prices upsized $345.6 million IPO
|
- Latigo priced an upsized $345.6M IPO at $18.00 per share for 19.2M shares to fund its non-opioid pain pipeline.
- Why it matters: Upsizing from 16M shares at $16–18 to 19.2M at $18 is a 27% bump on the $272M target and the third top-of-range biotech pricing this week. The money funds a direct run at Vertex’s Journavx, which cleared in January 2025 and managed roughly $90M in year one — soft enough that Latigo’s pitch is efficacy, not category creation: SPID48 of 62.1 in the high-dose arm of a 343-patient abdominoplasty Phase 2b, published in NEJM. Phase 3 bunionectomy starts this half on the FDA’s preferred pain model, the one Vertex used. Topline 2H27, so nothing resolves before then.
-
Source:
PR
-
More:
Fierce Biotech;
BioSpace
|
| 3 | Tarsus buys Alkeus for $450M, funds it with a $125M PIPE |
- Tarsus agreed to acquire Alkeus for $450M to secure gildeuretinol, a once-daily oral candidate in Phase 3 for Stargardt disease, alongside an oversubscribed $125M PIPE.
- Why it matters: $270M cash plus $180M in Tarsus stock, with up to $350M more contingent on gildeuretinol reaching market — and the $125M PIPE comes from Bain Capital Life Sciences and TCGX crossing over from Alkeus’s own cap table, which is how you fund a deal without touching the balance sheet. Stargardt has no approved therapy and roughly 36,000 US patients, but Belite Bio’s tinlarebant already won its Phase 3 and is in front of the FDA, so Tarsus is buying second position in a race it doesn’t lead. The asset has also flunked a Phase 3 in geographic atrophy. Pivotal readout is 2029.
-
Source:
Fierce Biotech
-
More:
PR
|
Everything Else that broke
- BioVie fell 50% after leaning on a new composite measure rather than its stated primary endpoint to make the case for bezisterim in Parkinson’s. — Fierce Biotech
- Vistagen’s social anxiety nasal spray failed to beat placebo in Phase 2 even at double dose, and the biotech is again pointing to a subpopulation. — Fierce Biotech
- PacBio promoted an internal veteran to CEO as Christian Henry stepped down and Q2 losses widened. — Fierce Biotech
- Context discontinued bispecific T-cell engager CT-95 to push its cash runway deeper into 2027. — Fierce Biotech
- Bavarian Nordic won EU pediatric expansion for IMVANEX in children aged 2 to under 12. — PR
- BioMarin raised 2026 guidance after Q2 revenue climbed 20% to $990M. — PR
- Aclaris secured Fast Track status for modzatinib in moderate to severe lichen planus. — PR
- Trevi started Phase 3 OCEAN-1 and expects OCEAN-2 to launch in Q3 2026. — PR
Deal Flow
|
BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
- Tarsus agreed to acquire Alkeus for $450M — $270M cash and $180M in stock, plus up to $350M in milestones — for Phase 3 Stargardt candidate gildeuretinol (see The Big 3). — Fierce Biotech
- Biogen closed its RayThera acquisition — $225M upfront plus up to $775M in milestones — adding small-molecule immunology assets with the lead program in Phase 1 since July. — PR
- Actimed regained exclusive global rights to S-oxprenolol from Faraday, ending a deal worth up to $126M in milestones. — Fierce Biotech
-
Energenesis and Taiwan Tanabe signed a joint development pact for ENERGI-F703DFU covering tech transfer and Taiwan NDA-enabling CMC work. — PR
VC / Private Financings
- LifeMine raised $263M for calcineurin activation inhibitor LIFE-001 across a $75M Series D and a $188M Series E led by Milky Way Investments, joined by Bezos Expeditions, Gates Frontier, RA Capital, GSK and ARCH Venture Partners. — Endpoints
IPOs / Follow-Ons
- Latigo priced an upsized $345.6M IPO at $18.00 per share for 19.2M shares (see The Big 3). — PR
- Tarsus placed an oversubscribed $125M PIPE backed by Bain Capital Life Sciences and TCGX, with existing holders ADAR1 and Sirenia participating (see The Big 3). — Fierce Biotech
Academic Corner - Phase 1 intracranial B7-H3-targeting CAR-T in recurrent glioblastoma showed no dose-limiting toxicities and encouraging clinical-benefit signals. — Nature Medicine
- Psilocybin-assisted therapy improved symptoms in 60 adults with treatment-resistant depression in an NHS-based randomized trial. — Nature Medicine
- Nature RDD highlighted the first dual BAFF and APRIL inhibitor to win FDA approval. — Nature RDD
|
